GlassScriptPhysician profile
Diego G Allende
NPI 1568789097
$4,354.18
in general payments reported to CMS, 2019-2025
22 companies · $1,811 in 2025
The $1,811 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $194 · 2021: $102 · 2022: $376 · 2023: $494 · 2024: $1,105 · 2025: $1,811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,410.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $757.89 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $665.78 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Phathom Pharmaceuticals, INC. | $436.23 | 2024-2025 | Voquezna |
| Amgen INC. | $377.66 | 2024-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $363.39 | 2022-2025 | Ozempic, Rybelsus |
| Antares Pharma, INC. | $250.72 | 2024-2025 | Xyosted |
| Pfizer INC. | $247.07 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $247.00 | 2021-2025 | |
| Shield Therapeutics INC | $175.11 | 2023-2025 | Accrufer |
| Exact Sciences Corporation | $170.63 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.64 | 2022-2024 | Jardiance, Tradjenta, Synjardy |
| Boston Scientific Corporation | $106.81 | 2019 | |
| Abbott Laboratories | $103.72 | 2022-2025 | Freestyle Libre 3, Eterna |
| Dexcom, INC. | $55.90 | 2024-2025 | Dexcom G6 Transmitter |
| Verity Pharmaceuticals INC. | $44.11 | 2024 | Tlando |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acella Pharmaceuticals, LLC | $37.06 | 2023 | NP Thyroid 60 |
| Novartis Pharmaceuticals Corporation | $36.89 | 2025 | |
| Glaxosmithkline, LLC. | $36.47 | 2021-2022 | |
| Nalu Medical, INC. | $31.62 | 2025 | Nalu Neurostimulation System |
| Mannkind Corporation | $20.93 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.84 | 2022 | |
| Tolmar, INC. | $13.71 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diego Allende listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.